Trametinib
Information
- Drug Name
- Trametinib
- Description
- Entry(CIViC)
- 62
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| MEK inhibitor-resistant (selumetinib, PD0325901, G... | DDX43 |
DDX43 OVEREXPRESSION ( ENST00000370336.5 ) DDX43 OVEREXPRESSION ( ENST00000370336.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a phase 1 clinical trial for the use of trameti... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Phase 1 trial of trametinib and docetaxel in patie... | NRAS | NRAS MUTATION NRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Phase 1 trial in 97 patients with melanoma (81 cut... | NRAS | NRAS MUTATION NRAS MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Phase 1 study of trametinib in 97 patients with me... | GNA11 | GNA11 MUTATION GNA11 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Phase 1 study of trametinib in 97 patients with me... | GNAQ | GNAQ MUTATION GNAQ MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in 16 NRAS mutant cell lines (me... | NRAS | NRAS MUTATION NRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| 6 head and neck cancer cell lines were tested for ... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Sensitivity | false | CIViC Evidence | detail |
| The Combi-v (NCT01597908) open-label, randomized p... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| In clinical trial NCT01072175, 43 patients with BR... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| In six NRAS mutant melanoma cell lines, concomitan... | NRAS | NRAS MUTATION NRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| BRAF mutations were identified in 9% of 108 cases ... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in melanoma cell lines. Inactivi... | BRAF |
BRAF p.Asp634Val (p.D634V) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Asp634Val (p.D634V) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in 293H cell line. Ectopic expre... | BRAF |
BRAF p.Leu637Arg (p.L637R) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Leu637Arg (p.L637R) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in 293H cell line. Ectopic expre... | BRAF |
BRAF p.Leu637Ser (p.L637S) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Leu637Ser (p.L637S) ( ENST00000646891.2, ENST00000644969.2, ENST00000288602.11, ENST00000496384.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in 293H cell line. Ectopic expre... | BRAF |
BRAF p.Leu637Gln (p.L637Q) ( ENST00000496384.7, ENST00000288602.11, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Leu637Gln (p.L637Q) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Preclinical study in 293H cell line. Ectopic expre... | BRAF |
BRAF p.Lys641Glu (p.K641E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Lys641Glu (p.K641E) ( ENST00000496384.7, ENST00000288602.11, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Case report of a phase 1 study in advanced melanom... | BRAF |
BRAF p.Leu637Val (p.L637V) ( ENST00000646891.2, ENST00000288602.11, ENST00000496384.7, ENST00000644969.2 ) BRAF p.Leu637Val (p.L637V) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Case report of a 47year old female patient with me... | BRAF | BRAF PPFIBP2-BRAF | Sensitivity | true | CIViC Evidence | detail |
| A 65 yr old male patient with metastatic acral len... | BRAF | BRAF KIAA1549-BRAF | Sensitivity | true | CIViC Evidence | detail |
| Analysis of BRAF fusions in 20,573 tumors, across ... | BRAF | BRAF ZKSCAN1-BRAF | Sensitivity | true | CIViC Evidence | detail |
| non-V600 BRAF mutations can be sensitive to clinic... | BRAF |
BRAF p.Gly636Cys (p.G636C) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Gly636Cys (p.G636C) ( ENST00000646891.2, ENST00000288602.11, ENST00000496384.7, ENST00000644969.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Patients who had histologically confirmed, unresec... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| In a study of 322 advanced melanoma patients with ... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a study of 322 advanced melanoma patients with ... | BRAF |
BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Of the 4,562 patients with lung cancers, 30 showed... | NRAS |
NRAS p.Gln61Lys (p.Q61K) ( ENST00000369535.5 ) NRAS p.Gln61Lys (p.Q61K) ( ENST00000369535.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Patients with BRAF V600E-mutant NSCLC (n=57) were ... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this study the authors screened for growth fact... | MET |
MET OVEREXPRESSION ( ENST00000318493.11 ) MET OVEREXPRESSION ( ENST00000318493.11 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a clinical trial (NCT01597908) of 704 metastati... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Trametinib can inhibit ARF-mediated ERK phosphoryl... | ARAF |
ARAF p.Ser214Cys (p.S214C) ( ENST00000377045.9 ) ARAF p.Ser214Cys (p.S214C) ( ENST00000377045.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a clinical trial (NCT01597908) of 704 metastati... | BRAF |
BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| This phase I/Ib two-part study evaluated trametini... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In this phase II trial, trametinib or docetaxel wa... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | false | CIViC Evidence | detail |
| Case study report including one patient with L597Q... | BRAF |
BRAF p.Leu637Gln (p.L637Q) ( ENST00000496384.7, ENST00000288602.11, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Leu637Gln (p.L637Q) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Approximately 2% of NSCLCs had RASA1 truncating mu... | RASA1 | RASA1 MUTATION RASA1 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In this trial, 142 patients with metastatic, BRAF ... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this trial, 142 patients with metastatic, BRAF ... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | false | CIViC Evidence | detail |
| Adjuvant dual treatment with BRAF inhibitor dabraf... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Adjuvant dual treatment with BRAF inhibitor dabraf... | BRAF |
BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Combination Dabrafenib and Trametinib treatment wa... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| Adding trametinib to gemcitabine does not improve ... | KRAS | KRAS G12/G13 KRAS G12/G13 | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In this Phase III trial (NCT01584648 COMBI-d), 423... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| In this Phase III trial (NCT01584648 COMBI-d), pre... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this Phase I and II study (NCT01072175) patient... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| In this Phase III trial (coBRIM, NCT01689519) of 4... | BRAF |
BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Lys (p.V640K) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Interim analysis of a basket trial evaluating the ... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| BRAF-fusion in "pan-negative" melanomas were ident... | BRAF | BRAF PAPSS1-BRAF | Sensitivity | true | CIViC Evidence | detail |
| A TRIM24-BRAF fusion was identified in a single pa... | BRAF | BRAF TRIM24-BRAF | Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study, authors analyzed BRAF V6... | BRAF |
BRAF V600E AMPLIFICATION ( ENST00000288602.11 ) BRAF V600E AMPLIFICATION ( ENST00000288602.11 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a case report, a patient with pancreatic cancer... | BRAF | BRAF APC BRAF APC | Sensitivity | true | CIViC Evidence | detail |
| In a BRAF-mutation inducible model in the NIH3T3 c... | BRAF |
BRAF p.Asp634Gly (p.D634G) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Asp634Gly (p.D634G) ( ENST00000646891.2, ENST00000496384.7, ENST00000644969.2, ENST00000288602.11 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a case report, a patient with urothelial carcin... | BRAF | BRAF NRF1-BRAF | Sensitivity | true | CIViC Evidence | detail |
| In a phase II basket trial (NCI-MATCH), patients w... | BRAF | BRAF MUTATION BRAF MUTATION | Sensitivity | false | CIViC Evidence | detail |
| In the setting of BRAF(V600E), NF1 loss resulted i... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a Phase I and II study (NCT01072175) of d... | BRAF | BRAF V600 BRAF V600 | Sensitivity | true | CIViC Evidence | detail |
| Expression of DUSP6 was associated with sensitivit... | DUSP6 | DUSP6 EXPRESSION DUSP6 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| In this screen of 218 solid cancer cell lines, KRA... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In this screen of 218 solid cancer cell lines, BRA... | BRAF | BRAF MUTATION BRAF MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Dabrafenib with trametinib provides higher respons... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| KRAS G12/G13 status was evaluated in cell-free DNA... | KRAS | KRAS G12/G13 KRAS G12/G13 | Sensitivity | false | CIViC Evidence | detail |
| An shDNA Screen identified synergy betwenn ERBB3 I... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| An shDNA screen identified synergy between ERBB3 I... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01990196 | Active, not recruiting | Phase 2 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | September 23, 2014 | September 30, 2025 |
| NCT03784014 | Active, not recruiting | Phase 3 | Molecular Profiling of Advanced Soft-tissue Sarcomas | October 19, 2019 | October 2025 |
| NCT02152995 | Active, not recruiting | Phase 2 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer | August 14, 2014 | January 25, 2025 |
| NCT03741101 | Active, not recruiting | Phase 2 | Treatment of NF1-related Plexiform Neurofibroma With Trametinib | June 10, 2019 | December 15, 2024 |
| NCT02231775 | Active, not recruiting | Phase 2 | Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | October 22, 2014 | April 1, 2025 |
| NCT03501368 | Active, not recruiting | Phase 1 | Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma | June 27, 2018 | August 2024 |
| NCT02015117 | Active, not recruiting | Phase 1 | Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | April 28, 2014 | September 27, 2024 |
| NCT01723202 | Active, not recruiting | Phase 2 | Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer | November 7, 2012 | December 31, 2022 |
| NCT03455764 | Active, not recruiting | Phase 1/Phase 2 | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | June 22, 2018 | September 30, 2025 |
| NCT03377361 | Active, not recruiting | Phase 1/Phase 2 | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | February 1, 2018 | March 11, 2024 |
| NCT03363217 | Active, not recruiting | Phase 2 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. | August 16, 2018 | March 1, 2027 |
| NCT03333343 | Active, not recruiting | Phase 1 | Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | January 29, 2018 | December 16, 2024 |
| NCT04940052 | Active, not recruiting | Phase 3 | Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer | November 15, 2021 | June 3, 2027 |
| NCT04452877 | Active, not recruiting | Phase 2 | A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | August 19, 2020 | November 21, 2024 |
| NCT03299088 | Active, not recruiting | Phase 1 | Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations | June 26, 2018 | June 2024 |
| NCT03225664 | Active, not recruiting | Phase 1/Phase 2 | Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced | February 3, 2018 | December 31, 2024 |
| NCT04417621 | Active, not recruiting | Phase 2 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | October 30, 2020 | September 30, 2024 |
| NCT04544111 | Active, not recruiting | Phase 2 | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | September 2, 2020 | September 2, 2025 |
| NCT03190915 | Active, not recruiting | Phase 2 | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | September 9, 2018 | September 22, 2024 |
| NCT02465060 | Active, not recruiting | Phase 2 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | August 17, 2015 | December 31, 2025 |
| NCT03149029 | Active, not recruiting | Phase 2 | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | November 27, 2017 | December 31, 2024 |
| NCT03087071 | Active, not recruiting | Phase 2 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | December 29, 2017 | January 31, 2025 |
| NCT03085056 | Active, not recruiting | Early Phase 1 | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | March 15, 2017 | September 2024 |
| NCT02642042 | Active, not recruiting | Phase 2 | Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer | July 18, 2016 | March 5, 2025 |
| NCT03065387 | Active, not recruiting | Phase 1 | Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation | October 31, 2017 | October 1, 2025 |
| NCT01972347 | Active, not recruiting | Phase 2 | Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma | October 2014 | May 2024 |
| NCT03026517 | Active, not recruiting | Phase 1 | Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma | January 2017 | January 2025 |
| NCT02070549 | Active, not recruiting | Phase 1 | Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction | March 10, 2014 | November 1, 2024 |
| NCT02858921 | Active, not recruiting | Phase 2 | Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma | November 8, 2017 | November 2024 |
| NCT02881242 | Active, not recruiting | Phase 2 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | January 30, 2018 | January 31, 2025 |
| NCT02910700 | Active, not recruiting | Phase 2 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | December 9, 2016 | December 8, 2024 |
| NCT02967692 | Active, not recruiting | Phase 3 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | February 17, 2017 | August 26, 2024 |
| NCT02079740 | Active, not recruiting | Phase 1/Phase 2 | Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | March 26, 2014 | March 7, 2025 |
| NCT01989585 | Active, not recruiting | Phase 1/Phase 2 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | March 24, 2014 | December 31, 2024 |
| NCT04111458 | Active, not recruiting | Phase 1 | A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | October 28, 2019 | October 31, 2024 |
| NCT04294160 | Active, not recruiting | Phase 1 | A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | July 22, 2020 | October 11, 2024 |
| NCT04489433 | Available | Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma | |||
| NCT04544202 | Available | Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection | |||
| NCT01979523 | Completed | Phase 2 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | October 23, 2013 | September 1, 2017 |
| NCT01584648 | Completed | Phase 3 | A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma | May 4, 2012 | February 28, 2019 |
| NCT01597908 | Completed | Phase 3 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma | June 4, 2012 | April 25, 2019 |
| NCT01682083 | Completed | Phase 3 | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | January 8, 2013 | July 31, 2023 |
| NCT01740648 | Completed | Phase 1 | Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer | November 26, 2012 | September 29, 2021 |
| NCT01750918 | Completed | Phase 1/Phase 2 | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | December 19, 2012 | June 18, 2020 |
| NCT01767454 | Completed | Phase 1 | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | February 12, 2013 | September 4, 2015 |
| NCT01827384 | Completed | Phase 2 | MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | January 7, 2014 | October 8, 2021 |
| NCT01928940 | Completed | Phase 2 | Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) | August 15, 2013 | July 4, 2016 |
| NCT01935973 | Completed | Phase 1 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 30, 2013 | September 8, 2015 |
| NCT01938443 | Completed | Phase 1 | A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | November 18, 2013 | June 23, 2016 |
| NCT01964924 | Completed | Phase 2 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | October 2, 2013 | April 23, 2018 |
| NCT01336634 | Completed | Phase 2 | Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | August 5, 2011 | January 7, 2021 |
| NCT01989598 | Completed | Phase 2 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | October 30, 2013 | September 28, 2020 |
| NCT02016729 | Completed | Phase 1 | A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | April 1, 2014 | July 31, 2017 |
| NCT02027961 | Completed | Phase 1 | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | December 20, 2013 | April 24, 2018 |
| NCT02034110 | Completed | Phase 2 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | March 12, 2014 | December 10, 2021 |
| NCT02039947 | Completed | Phase 2 | Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | February 21, 2014 | February 14, 2018 |
| NCT02042443 | Completed | Phase 2 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery | February 2014 | April 30, 2017 |
| NCT02065063 | Completed | Phase 1 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | April 22, 2014 | June 23, 2016 |
| NCT02083354 | Completed | Phase 2 | Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma | March 18, 2014 | April 19, 2021 |
| NCT02110355 | Completed | Phase 1 | A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma | December 19, 2014 | December 27, 2018 |
| NCT02124772 | Completed | Phase 1/Phase 2 | Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations | January 15, 2015 | December 29, 2020 |
| NCT02130466 | Completed | Phase 1/Phase 2 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | May 29, 2014 | July 14, 2021 |
| NCT02292173 | Completed | Phase 1 | Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | February 18, 2015 | January 2021 |
| NCT02296112 | Completed | Phase 2 | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | January 2015 | April 16, 2021 |
| NCT02367859 | Completed | Phase 2 | Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma | July 17, 2017 | June 26, 2019 |
| NCT02399943 | Completed | Phase 2 | A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer | June 2015 | March 31, 2022 |
| NCT02428270 | Completed | Phase 2 | A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | April 2016 | October 27, 2022 |
| NCT02439411 | Completed | Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain | March 3, 2015 | September 2016 | |
| NCT02684058 | Completed | Phase 2 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | December 28, 2017 | April 28, 2023 |
| NCT02705963 | Completed | Phase 1 | A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors | October 20, 2016 | August 29, 2019 |
| NCT03076164 | Completed | Phase 1/Phase 2 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | March 1, 2017 | December 18, 2020 |
| NCT03148275 | Completed | Phase 2 | Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery | June 20, 2017 | June 23, 2023 |
| NCT03317119 | Completed | Phase 1 | Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery | April 11, 2018 | July 14, 2023 |
| NCT03352947 | Completed | Phase 2 | Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma | November 3, 2017 | November 27, 2020 |
| NCT03428126 | Completed | Phase 2 | Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | March 21, 2018 | May 5, 2022 |
| NCT03434262 | Completed | Phase 1 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | March 5, 2018 | May 24, 2024 |
| NCT03516214 | Completed | Phase 1 | EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations | April 25, 2018 | November 27, 2023 |
| NCT03551626 | Completed | Phase 3 | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes | August 29, 2018 | September 16, 2021 |
| NCT03714958 | Completed | Phase 1 | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type | December 20, 2018 | September 12, 2023 |
| NCT04059224 | Completed | Phase 2 | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma | January 28, 2019 | June 30, 2023 |
| NCT04310397 | Completed | Phase 2 | Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | January 29, 2020 | October 9, 2023 |
| NCT04487106 | Completed | Phase 2 | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | July 21, 2020 | February 9, 2023 |
| NCT04967079 | Completed | Phase 1 | Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | August 1, 2021 | March 26, 2024 |
| NCT05260684 | Completed | Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US | January 17, 2022 | December 31, 2023 | |
| NCT05616923 | Completed | Phase 1 | Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea | November 1, 2021 | December 31, 2022 |
| NCT02416232 | No longer available | Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma | |||
| NCT06456138 | Not yet recruiting | Phase 1/Phase 2 | Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC | July 1, 2024 | December 31, 2028 |
| NCT05658640 | Not yet recruiting | Phase 1/Phase 2 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies | April 1, 2023 | April 1, 2029 |
| NCT05275374 | Not yet recruiting | Phase 1/Phase 2 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | December 2024 | December 2026 |
| NCT04892017 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors | June 15, 2021 | August 2028 |
| NCT04485559 | Recruiting | Phase 1 | Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | December 9, 2020 | December 31, 2027 |
| NCT05876806 | Recruiting | Phase 2 | Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations | June 20, 2023 | March 2026 |
| NCT02925234 | Recruiting | Phase 2 | The Drug Rediscovery Protocol (DRUP Trial) | August 2016 | December 2027 |
| NCT05358249 | Recruiting | Phase 1/Phase 2 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | October 24, 2022 | June 16, 2027 |
| NCT05440942 | Recruiting | Phase 1 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | January 19, 2023 | September 2027 |
| NCT04666272 | Recruiting | Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection | December 31, 2020 | July 31, 2029 | |
| NCT04675710 | Recruiting | Phase 2 | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | June 24, 2021 | June 30, 2024 |
| NCT05518110 | Recruiting | Phase 2 | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer | May 31, 2023 | April 15, 2025 |
| NCT05372354 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | October 18, 2022 | October 12, 2026 |
| NCT03563729 | Recruiting | Phase 2 | Melanoma Metastasized to the Brain and Steroids | June 6, 2018 | June 6, 2028 |
| NCT06346067 | Recruiting | Phase 3 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | April 29, 2024 | December 2028 |
| NCT05180825 | Recruiting | Phase 2 | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy | May 5, 2022 | December 1, 2031 |
| NCT05668585 | Recruiting | Phase 1/Phase 2 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | December 8, 2022 | April 11, 2027 |
| NCT05171374 | Recruiting | pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE | September 30, 2021 | September 30, 2024 | |
| NCT05159245 | Recruiting | Phase 2 | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs | December 10, 2021 | November 25, 2026 |
| NCT05907304 | Recruiting | Phase 1 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | August 17, 2023 | November 2025 |
| NCT03825289 | Recruiting | Phase 1 | Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer | January 18, 2019 | January 18, 2026 |
| NCT03091257 | Recruiting | Phase 1 | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | June 21, 2017 | September 15, 2024 |
| NCT03899155 | Recruiting | Phase 2 | Pan Tumor Rollover Study | August 9, 2019 | August 25, 2029 |
| NCT03975231 | Recruiting | Phase 1 | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | September 14, 2020 | April 30, 2025 |
| NCT03975829 | Recruiting | Phase 4 | Pediatric Long-Term Follow-up and Rollover Study | November 4, 2019 | May 29, 2026 |
| NCT04961619 | Recruiting | Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. | December 1, 2021 | December 30, 2024 | |
| NCT04943224 | Recruiting | Phase 2 | Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients | April 1, 2021 | June 23, 2026 |
| NCT04116541 | Recruiting | Phase 2 | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. | January 28, 2020 | November 2026 |
| NCT04185883 | Recruiting | Phase 1 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | December 17, 2019 | December 31, 2027 |
| NCT04201457 | Recruiting | Phase 1/Phase 2 | A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | January 17, 2020 | June 30, 2029 |
| NCT04903119 | Recruiting | Phase 1 | Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | June 1, 2022 | March 31, 2027 |
| NCT04238624 | Recruiting | Phase 2 | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | January 20, 2020 | June 20, 2024 |
| NCT04303403 | Recruiting | Phase 1 | Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma | July 31, 2018 | March 31, 2024 |
| NCT05849662 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | May 10, 2024 | December 2029 |
| NCT03340506 | Recruiting | Phase 4 | Dabrafenib and/or Trametinib Rollover Study | December 28, 2017 | December 21, 2027 |
| NCT02538627 | Terminated | Phase 1 | Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | August 2015 | October 5, 2016 |
| NCT03232892 | Terminated | Phase 2 | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer | February 13, 2018 | September 11, 2019 |
| NCT03272464 | Terminated | Phase 1 | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | May 29, 2019 | December 27, 2019 |
| NCT02410863 | Terminated | Phase 2 | Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma | November 2015 | August 2018 |
| NCT05435846 | Terminated | Phase 1 | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | August 10, 2022 | May 31, 2024 |
| NCT02314143 | Terminated | Phase 2 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib | November 13, 2013 | January 19, 2017 |
| NCT02258607 | Terminated | Phase 1 | Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase | March 11, 2015 | February 27, 2017 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT01940809 | Terminated | Phase 1 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | August 28, 2013 | March 4, 2022 |
| NCT01912625 | Terminated | Phase 1 | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | October 28, 2013 | February 24, 2023 |
| NCT01907815 | Terminated | Phase 2 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | October 2013 | January 2016 |
| NCT01721603 | Terminated | Phase 2 | Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | April 2013 | January 2016 |
| NCT04566133 | Terminated | Phase 2 | Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | February 15, 2022 | December 31, 2022 |
| NCT04801966 | Terminated | N/A | Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study | September 23, 2021 | December 30, 2022 |
| NCT01701037 | Terminated | Phase 2 | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | January 2013 | April 2015 |
| NCT05071183 | Terminated | Phase 1/Phase 2 | A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors | September 23, 2021 | March 1, 2023 |
| NCT02974725 | Terminated | Phase 1 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | February 24, 2017 | April 24, 2024 |
| NCT02974803 | Terminated | Phase 2 | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | February 9, 2018 | July 29, 2020 |
| NCT02703571 | Terminated | Phase 1 | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | June 29, 2016 | September 24, 2019 |
| NCT02580708 | Terminated | Phase 1/Phase 2 | Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer | September 30, 2015 | June 27, 2016 |
| NCT03087448 | Terminated | Phase 1 | Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) | September 9, 2017 | April 30, 2022 |
| NCT03244956 | Unknown status | Phase 2 | Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer | December 27, 2017 | December 2022 |
| NCT03754179 | Unknown status | Phase 1/Phase 2 | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma | January 23, 2018 | July 1, 2022 |
| NCT02230553 | Unknown status | Phase 1/Phase 2 | Lapatinib Plus Trametinib in KRAS Mutant NSCLC | October 2014 | December 2019 |
| NCT03668431 | Unknown status | Phase 2 | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | October 15, 2018 | December 1, 2022 |
| NCT03631953 | Unknown status | Phase 1 | Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas | September 30, 2019 | September 1, 2022 |
| NCT03088176 | Unknown status | Phase 1 | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | June 25, 2017 | June 30, 2021 |
| NCT02097225 | Unknown status | Phase 1 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | May 29, 2014 | |
| NCT02625337 | Unknown status | Phase 2 | Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients | January 2016 | December 2018 |
| NCT02915666 | Withdrawn | Phase 1 | A Clinical Trial of Patients With Melanoma | October 2016 | July 17, 2017 |
| NCT02447939 | Withdrawn | Phase 1 | Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma | May 2017 | December 2018 |
| NCT02140840 | Withdrawn | Phase 2 | UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | March 2015 | April 2016 |
| NCT02357732 | Withdrawn | Phase 1 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | August 2015 | August 2015 |
| NCT02672358 | Withdrawn | Phase 2 | Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC | September 3, 2018 | December 7, 2020 |
| NCT04739566 | Withdrawn | Phase 2 | Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer | January 22, 2021 | December 22, 2023 |
| NCT05299580 | Withdrawn | Phase 2 | "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" | February 18, 2021 | March 30, 2023 |
| NCT01938456 | Withdrawn | Phase 1 | Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer | October 2013 | July 2014 |
| NCT05677373 | Withdrawn | Phase 1/Phase 2 | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma | January 13, 2023 | July 31, 2025 |
| NCT02143050 | Withdrawn | Phase 1/Phase 2 | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | September 2014 | November 17, 2017 |
| NCT02300935 | Withdrawn | Phase 1 | Study of Trametinib and Nab-paclitaxel in Patients With Melanoma | December 2015 | January 20, 2016 |
| NCT02342600 | Withdrawn | Phase 2 | SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) | January 2017 | |
| NCT02939846 | Withdrawn | Phase 1 | Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours | May 2017 | December 2018 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Mekinist
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2013
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2016
- Target (Drug list of Screening Committee of Anticancer Drugs)
- MEK**
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- メラノーマ（BRAF/V600E/K）